Today: 30 April 2026
DBS stock tops S$58 as Singapore bank rally rolls on; investors eye Feb 9 results
7 January 2026
1 min read

DBS stock tops S$58 as Singapore bank rally rolls on; investors eye Feb 9 results

Singapore, Jan 7, 2026, 14:52 SGT — Regular session

DBS Group Holdings Ltd (D05.SI) shares edged higher on Wednesday and briefly touched S$58.80, keeping the stock near the top of its 52-week range. The counter was last up 0.6% at S$58.25 in afternoon trade, after closing at S$57.93 on Tuesday.

The move matters because Singapore’s banks are heavyweights in local portfolios and a key driver of the benchmark index. Investors have been treating high-dividend names as a way to lock in income as they reassess the outlook for interest rates.

Singapore bank stocks have extended a multi-week rally that pushed the Straits Times Index to a record high of 4,765.29 earlier on Wednesday, with OCBC and UOB also in focus, The Straits Times reported. Morningstar director of Asia equity research Lorraine Tan said dividend stocks were a “proxy to holding Singapore government bonds”, even as she flagged richer valuations after the run-up. Analysts told the paper DBS is seen lifting its quarterly dividend by 6 Singapore cents to 66 cents in 2026 and paying an extra 15 cents a share as a capital-return dividend through fiscal 2027. The Straits Times

For DBS, the market debate is whether payout strength can offset a tougher rate backdrop. A key pressure point is the bank’s net interest margin — the gap between what it earns on loans and what it pays on deposits — which typically narrows when rates fall.

On charts, the day’s high at S$58.80 is the next level traders are watching. A slide back below Tuesday’s S$57.93 close would put the recent breakout at risk and could draw profit-taking after the sharp run.

But the rally leaves less room for disappointment if fourth-quarter results show weaker margins or higher credit costs. Any shift in guidance on dividends, buybacks or loan growth could also swing sentiment quickly.

Stock Market Today

  • Chimeric Therapeutics Completes ASX Security Consolidation to Streamline Capital Structure
    April 29, 2026, 9:09 PM EDT. Chimeric Therapeutics Ltd (ASX: CHM) has finalised a previously approved security consolidation involving its ordinary shares, options, and performance rights. The consolidation, approved by shareholders on April 17, 2026, was officially recorded with the Australian Securities Exchange on April 29, signalling completion of the capital reorganisation process. This move aims to streamline Chimeric's capital base, potentially impacting trading activity and investor perception. The biotech firm, focused on therapeutic development, currently holds a market capitalisation of A$6.63 million with average daily trading volume of 220,715 shares. The consolidation clarifies its security structure, supporting future capital management efforts amid ongoing market challenges.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
DroneShield stock cools after JPMorgan drops below 5% stake — what ASX:DRO investors watch next
Previous Story

DroneShield stock cools after JPMorgan drops below 5% stake — what ASX:DRO investors watch next

Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says
Next Story

Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says

Go toTop